64B13-18.002 : Formulary of Topical Ocular Pharmaceutical Agents - Florida Administrative Rules, Law, Code, Register

Florida Department of State and Division of Library and Information Services

Rule: 64B13-18.002 Prev Up Next

Rule Title: Formulary of Topical Ocular Pharmaceutical Agents
Department:	DEPARTMENT OF HEALTH	Add to MyFLRules Favorites
Division:	Board of Optometry
Chapter:	TOPICAL OCULAR PHARMACEUTICAL AGENTS

Latest version of the final adopted rule presented in Florida Administrative Code (FAC):

	Effective Date:	12/12/2023
	History Notes:	Rulemaking Authority 463.005, 463.0055(2)(a) FS. Law Implemented 463.0055 FS. History–New 3-30-87, Amended 4-5-88, 5-7-90, Formerly 21-18.002, Amended 5-10-92, 1-29-93, Formerly 21Q-18.002, Amended 8-31-93, 7-30-94, Formerly 61F8-18.002, Amended 2-11-96, 4-21-96, 1-12-97, 6-8-97, Formerly 59V-18.002, Amended 6-15-00, 6-7-05, 6-10-06, 6-26-08, 10-16-08, 3-23-09, 6-28-09, 10-18-09, 4-21-10, 12-26-10, 7-21-11, 11-11-12, 11-29-13, 12-9-13, 4-10-14, 8-14-15, 1-20-17, 8-31-18, 1-25-19, 8-5-19, 3-13-20, 1-5-21, 9-4-21, 5-23-22, 12-12-23.
	References in this version:	No reference(s).

History of this Rule since Jan. 6, 2006

Section	Description	ID	Publish Date

Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	27674311	Effective: 12/12/2023
Proposed 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	27543555	9/13/2023 Vol. 49/178
Development 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	27482542	8/28/2023 Vol. 49/167
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	25833736	Effective: 05/23/2022
Proposed 64B13-18.002	The Board proposes the rule amendment to update the rule and the formulary of topical ocular pharmaceutical agents.	25599093	2/23/2022 Vol. 48/37
Development 64B13-18.002	The Board proposes the rule amendment to update the rule and the formulary of topical ocular pharmaceutical agents.	25540796	2/7/2022 Vol. 48/25
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	25012340	Effective: 09/04/2021
Proposed 64B13-18.002	The Board proposes the rule amendment to update the rule and the formulary of topical ocular pharmaceutical agents.	24580690	5/26/2021 Vol. 47/102
Development 64B13-18.002	The Board proposes the rule amendment to update the rule and the formulary of topical ocular pharmaceutical agents.	24510656	5/7/2021 Vol. 47/89
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	24027402	Effective: 01/05/2021
Change 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	23759973	10/14/2020 Vol. 46/201
Proposed 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	23461892	7/24/2020 Vol. 46/144
Withdrawal 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	23461601	7/24/2020 Vol. 46/144
Proposed 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	23423868	7/13/2020 Vol. 46/135
Development 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	23347723	6/16/2020 Vol. 46/117
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	22966707	Effective: 03/13/2020
Proposed 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	22591123	11/13/2019 Vol. 45/221
Development 64B13-18.002	The Board proposes the rule amendment to update the formulary of topical ocular pharmaceutical agents.	22520313	10/23/2019 Vol. 45/207
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	22155108	Effective: 08/05/2019
Proposed 64B13-18.002	The purpose of the amendment is to add item to the formulary.	21710654	4/9/2019 Vol. 45/69
Development 64B13-18.002	The purpose of the amendment is to add item to the formulary.	21652260	3/22/2019 Vol. 45/57
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	21361939	Effective: 01/25/2019
Change 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	21003912	10/16/2018 Vol. 44/202
Proposed 64B13-18.002	To add a topical ocular pharmaceutical agent to the formulary.	20918067	9/21/2018 Vol. 44/185
Development 64B13-18.002	The Board proposes the development of a rule amendment to add an item to the TOPA formulary rule.	20854338	9/4/2018 Vol. 44/172
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	20641229	Effective: 08/31/2018
Proposed 64B13-18.002	The Board proposes the rule amendment to add an item to the formulary rule.	20344603	4/26/2018 Vol. 44/82
Development 64B13-18.002	The Board proposes the development of a rule amendment to add an item to the formulary rule.	20283105	4/11/2018 Vol. 44/71
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	18448253	Effective: 01/20/2017
Correction 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	18110111	10/6/2016 Vol. 42/195
Proposed 64B13-18.002	To add item to formulary rule.	18056276	9/27/2016 Vol. 42/188
Development 64B13-18.002	To add item to formulary rule.	17985078	9/9/2016 Vol. 42/176
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	16139556	Effective: 08/14/2015
Proposed 64B13-18.002	To update the concentration percentage of a topical ocular pharmaceutical agent.	15885319	4/13/2015 Vol. 41/71
Development 64B13-18.002	To update the concentration percentage of a topical ocular pharmaceutical agent.	15824888	3/25/2015 Vol. 41/58
Development 64B13-18.002	To add an item to subsection (9).	15722747	2/27/2015 Vol. 41/40
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	14373186	Effective: 04/10/2014
Proposed 64B13-18.002	The Board proposes the rule amendment to add a new agent.	14187722	2/14/2014 Vol. 40/31
Development 64B13-18.002	The Board proposes the rule amendment to add a new agent.	14098579	1/24/2014 Vol. 40/16
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	13874218	Effective: 12/09/2013
Correction 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	13723674	10/25/2013 Vol. 39/209
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	13650148	Effective: 10/20/2013
Proposed 64B13-18.002	The Board proposes the rule amendment to delete unnecessary language and add new language to update the rule in accordance with Chapter 2013-26, Laws of Florida.	13646171	10/8/2013 Vol. 39/196
Development 64B13-18.002	The Board proposes the rule amendment to delete unnecessary language and add new language to update the rule in accordance with Chapter 2013-26, Laws of Florida.	13533748	9/17/2013 Vol. 39/181
Correction 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	13533166	9/17/2013 Vol. 39/181
Proposed 64B13-18.002	The Board proposes the rule amendment to add a new compound to the existing formulary of topical ocular pharmaceutical agents.	13410849	8/21/2013 Vol. 39/163
Development 64B13-18.002	The Board proposes the rule amendment to add a new compound to the existing formulary of topical ocular pharmaceutical agents rule .	13305022	7/29/2013 Vol. 39/146
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	12034322	Effective: 11/11/2012
Change 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	11827227	8/3/2012 Vol. 38/31
Proposed 64B13-18.002	The Board is adding the drug, Natacyn, to the formulary.	11671542	6/29/2012 Vol. 38/26
Development 64B13-18.002	The Board is adding the drug, Natacyn, to the formulary.	11506351	5/18/2012 Vol. 38/20
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	10119833	Effective: 07/21/2011
Proposed 64B13-18.002	The Board is correcting the concentration percentage of Bromfenac, increasing the concentration of Gatifloxacin and adding the anti-allergy medication Alcaftadine.	9924087	5/20/2011 Vol. 37/20
Withdrawal 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	9923796	5/20/2011 Vol. 37/20
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	9363330	Effective: 12/26/2010
Proposed 64B13-18.002	The Board is correcting the concentration percentage of Bromfenac and permits the prescription of a higher concentration of medication.	9434237	12/3/2010 Vol. 36/48
Development 64B13-18.002	The purpose of this rule amendment is to permit the prescription of a higher concentration of the medication.	9342281	11/5/2010 Vol. 36/44
Proposed 64B13-18.002	The Board is correcting the concentration percentage of Bromfenac and the spelling of Nepafenac.	9137708	9/17/2010 Vol. 36/37
Development 64B13-18.002	The Board is correcting the concentration percentage of Bromfenac and the spelling of Nepafenac.	9024218	8/20/2010 Vol. 36/33
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	8513610	Effective: 04/21/2010
Change 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	8344636	3/5/2010 Vol. 36/09
Proposed 64B13-18.002	The Board is adding the drug, Besivance, to the formulary.	8148502	1/15/2010 Vol. 36/02
Development 64B13-18.002	The Board is adding the drug, Resivance, to the formulary.	8024827	12/18/2009 Vol. 35/50
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	7578142	Effective: 10/18/2009
Proposed 64B13-18.002	The purpose of the amendment is to add two additional pharmaceutical agents to the rule, which a certified optometrist is qualified to administer and prescribe in the practice of optometry.	7372696	7/17/2009 Vol. 35/28
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	7302759	Effective: 06/28/2009
Development 64B13-18.002	The purpose of the amendments is to add two additional pharmaceutical agents to the rule, which a certified optometrist is qualified to administer and prescribe in the practice of optometry.	7310131	6/26/2009 Vol. 35/25
Proposed 64B13-18.002	The purpose of the amendment is to correct the maximum permitted concentration of olopatadine.	7082375	5/8/2009 Vol. 35/18
Development 64B13-18.002	The purpose of the amendment is to correct the maximum permitted concentration of olopatadine.	6948224	3/27/2009 Vol. 35/12
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	6906514	Effective: 03/23/2009
Proposed 64B13-18.002	The Board proposes the rule amendment to adopt the updated revisions recommended by the Topical Optical Pharmaceutical Agents Committee.	6523752	12/19/2008 Vol. 34/51
Development 64B13-18.002	To adopt the updated revisions recommended by the Topical Optical Pharmaceutical Agents Committee.	6367291	11/7/2008 Vol. 34/45
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	6241579	Effective: 10/16/2008
Proposed 64B13-18.002	The purpose of the amendment is to incorporate a new medication requested by the Florida Optometric Association, to which the TOPA Committee did not raise an objection, and to implement the Board’s determination that Azasite ....	6007615	8/22/2008 Vol. 34/34
Development 64B13-18.002	The purpose of the amendment is to incorporate a new medication requested by the Florida Optometric Association, to which the TOPA Committee did not raise an objection, and to implement the Board’s determination that Azasite ....	5915174	8/1/2008 Vol. 34/31
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	5762981	Effective: 06/26/2008
Proposed 64B13-18.002	The purpose of the amendment is to add medications to the Formulary of Topical Ocular Pharmaceutical Agents at the request of the Florida Optometric Association as approved by the TOPA Committee Members.	5564325	5/2/2008 Vol. 34/18
Development 64B13-18.002	The purpose and effect is to add medications to the Formulary of Topical Ocular Pharmaceutical Agents at the request of the Florida Optometric Association as approved by the TOPA Committee Members.	5497686	4/11/2008 Vol. 34/15
Final 64B13-18.002	Formulary of Topical Ocular Pharmaceutical Agents	2454020	Effective: 06/10/2006
Proposed 64B13-18.002	The Board proposes to update the existing language in this rule to add new pharmaceutical agents.	120782	3/3/2006 Vol. 32/09
Development 64B13-18.002	The Board proposes to update the existing language in this rule to add new pharmaceutical agents.	78102	2/3/2006 Vol. 32/05

Under Florida law, E-mail addresses are public records. If you do not want your E-mail address released in response to a public records request, do not send electronic mail to this entity. Instead, contact this office by phone or in writing.